What is the recommended dosing of Symbicort (budesonide/formoterol) for adults and children?

Symbicort Dosing

For asthma, adults and adolescents ≥12 years should use 2 inhalations of Symbicort 80/4.5 or 160/4.5 twice daily (morning and evening, approximately 12 hours apart), with a maximum dose of Symbicort 160/4.5 two inhalations twice daily; children 6 to <12 years should use 2 inhalations of Symbicort 80/4.5 twice daily. 1

Asthma Dosing by Age Group

Adults and Adolescents (≥12 Years)

• Starting dose: 2 inhalations of Symbicort 80/4.5 or 160/4.5 twice daily, based on asthma severity and current control 1
• Maximum dose: Symbicort 160/4.5, two inhalations twice daily 1
• Dose adjustment: If inadequate response after 1-2 weeks on Symbicort 80/4.5, consider switching to Symbicort 160/4.5 for additional control 1
• Timing: Administer morning and evening, approximately 12 hours apart 1

Pediatric Patients (6 to <12 Years)

• Dose: 2 inhalations of Symbicort 80/4.5 twice daily 1
• Important limitation: Only the 80/4.5 strength is appropriate for this age group 1

Children <6 Years

• Symbicort is not indicated for children under 6 years of age 1

COPD Dosing

• Recommended dose: Symbicort 160/4.5, two inhalations twice daily 1
• Important note: Symbicort 160/4.5 is the only strength indicated for COPD treatment 1

Administration Technique

• Priming: Prime before first use by releasing 2 test sprays into the air (away from face), shaking well for 5 seconds before each spray 1
• Re-priming: Prime again if inhaler unused for >7 days or if dropped 1
• Post-inhalation: Rinse mouth with water without swallowing after each use 1
• Route: Orally inhaled only 1

Critical Dosing Limitations

• Do not exceed prescribed dose: More frequent administration or higher number of inhalations than 2 inhalations twice daily is not recommended, as higher formoterol doses increase adverse effect risk 1
• No additional LABA: Patients using Symbicort should not use additional long-acting beta-agonists for any reason 1
• Rescue medication: Use a short-acting beta2-agonist (SABA) for acute symptom relief between doses, not additional Symbicort 1

Maintenance and Reliever Therapy (SMART/MART) Approach

For moderate-to-severe persistent asthma (Steps 3-4), the 2020 NAEPP guidelines strongly recommend ICS-formoterol as both daily controller and reliever therapy, which provides superior exacerbation reduction compared to higher-dose ICS alone or same-dose ICS-LABA with SABA rescue. 2, 3

SMART Dosing Regimen

• Maintenance: Budesonide-formoterol 160/4.5 μg, one inhalation once or twice daily (Step 3) or two inhalations twice daily (Step 4) 4
• Reliever: Additional inhalations of budesonide-formoterol 160/4.5 μg, one inhalation as needed for symptom relief 4
• Maximum daily total: Up to 12 inhalations in any single day for adults and adolescents (delivering 54 μg formoterol total) 4
• Evidence base: This approach reduces severe exacerbations at lower overall ICS exposure compared to fixed-dose regimens 4, 5

Important SMART Caveats

• FDA labeling vs. guidelines: The FDA-approved Symbicort labeling does not explicitly include SMART dosing, but the 2020 NAEPP guidelines strongly recommend this approach for Steps 3-4 2, 3, 1
• Formoterol-specific: SMART has only been validated with formoterol-containing ICS combinations, not other LABAs 4
• Patient education essential: Requires careful explanation and preferably a written asthma action plan to ensure proper self-management 4

Onset and Duration of Benefit

• Rapid onset: Improvement in asthma control can occur within 15 minutes of beginning treatment 1
• Maximum benefit: May not be achieved for 2 weeks or longer after starting treatment 1
• Individual variation: Time to onset and degree of symptom relief varies among patients 1

Common Pitfalls to Avoid

• Not using for acute relief: Symbicort is not indicated for relief of acute bronchospasm in either asthma or COPD 1
• Wrong strength for children: Never use Symbicort 160/4.5 in children 6 to <12 years 1
• Wrong strength for COPD: Never use Symbicort 80/4.5 for COPD; only the 160/4.5 strength is indicated 1
• Exceeding maximum dose: Do not exceed 2 inhalations twice daily of the prescribed strength in standard fixed-dose regimens 1